Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP ≥ 400 ng/ml

Marino Venerito; Joerg Trojan; P Mollon; Bruno Daniele; Florence Marteau; Y Li; Q Xu; Fabio Piscaglia; R Zaucher; Debashis Sarker; H. Y. Lim; Robin Katie Kelley

doi:https://doi.org/10.1055/s-0041-1733734

doi.org/10.1055/s-0041-1733734

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP ≥ 400 ng/ml

,

,

..., Robin Katie Kelley

14

Zeitschrift Fur Gastroenterologie1.30

Published: Sep 1, 2021

Abstract

Cabozantinib (CAB) and ramucirumab (RAM) are approved for the treatment of adults with hepatocellular carcinoma (HCC) following sorafenib (SOR); RAM is restricted for use in patients with a serum α-fetoprotein (AFP) ≥400 ng/ml. The matching-adjusted indirect comparison (MAIC) evaluated the efficacy and safety of both agents after SOR in HCC patients with AFP≥400...

Paper Fields

Paper Details

Title

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP ≥ 400 ng/ml

DOI

doi.org/10.1055/s-0041-1733734

Published Date

Sep 1, 2021

Journal

Zeitschrift Fur Gastroenterologie

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History